Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genor Biopharma Holdings Limited ( (HK:6998) ) has shared an announcement.
Edding Genor Group Holdings has convened its annual general meeting for 26 June 2026 in Shanghai, where shareholders will review and adopt the audited financial statements for the year ended 31 December 2025. The meeting will also consider the re-election of six directors, authorization of board-determined director remuneration, and the re-appointment of Ernst & Young as auditor for the 2026 financial year.
Shareholders will vote on granting the board a general mandate to repurchase up to 10% of the company’s issued shares, as well as a mandate to issue, allot and deal with additional shares, including any treasury shares. These proposed mandates would give the board added flexibility over capital management and share issuance, potentially influencing the company’s capital structure, liquidity, and shareholder returns.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange. The group operates in the biopharmaceutical sector, focusing on innovative therapies and leveraging capital-market access in Hong Kong to support its growth and operations in mainland China and beyond.
Average Trading Volume: 1,461,040
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.1B
For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.